(Q37378694)

20 August 2017

1 reference

title

Current considerations in the treatment of generalized anxiety disorder (English)

1 reference

20 August 2017

0 references

Martin A Katzman

1

1 reference

20 August 2017

language of work or name

1 reference

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

23

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

103-120

1 reference

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923020-00002

Psychiatric correlates of behavioral inhibition in young children of parents with and without psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923020-00002

Behavioral inhibition in children of parents with panic disorder and agoraphobia. A controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923020-00002

Comorbidity of parental anxiety disorders as risk for childhood-onset anxiety in inhibited children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923020-00002

Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923020-00002

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923020-00002

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923020-00002

A brief measure for assessing generalized anxiety disorder: the GAD-7.

21 January 2018

1 reference

12 December 2020

Stress and brain atrophy

1 reference

12 December 2020

Further validation of a cognitive-behavioral model of generalized anxiety disorder: diagnostic and symptom specificity.

1 reference

12 December 2020

Cognitive-behavioral treatment of late-life generalized anxiety disorder

1 reference

12 December 2020

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

12 December 2020

Treating generalized anxiety disorder with cognitive-behavioral therapy

1 reference

12 December 2020

Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine

1 reference

12 December 2020

Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32.

1 reference

12 December 2020

Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study

1 reference

12 December 2020

The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

1 reference

12 December 2020

Anxiety sensitivity within the anxiety disorders: disorder-specific sensitivities and depression comorbidity

1 reference

12 December 2020

Adolescent social anxiety as an outcome of inhibited temperament in childhood

1 reference

12 December 2020

The functioning and well-being of depressed patients. Results from the Medical Outcomes Study

1 reference

12 December 2020

Efficacy of sertraline in a 12-week trial for generalized anxiety disorder

1 reference

12 December 2020

Development and validation of the Penn State Worry Questionnaire

1 reference

12 December 2020

The Intolerance of Uncertainty Scale: psychometric properties of the English version

1 reference

12 December 2020

Depressive episodes--evidence for a causal role of primary anxiety disorders?

1 reference

12 December 2020

Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone

1 reference

12 December 2020

Generalized anxiety disorder: A comorbid disease

1 reference

12 December 2020

Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database

1 reference

12 December 2020

Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort

1 reference

12 December 2020

Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study.

1 reference

12 December 2020

Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations

1 reference

12 December 2020

Economic evidence in anxiety disorders: a review

1 reference

12 December 2020

Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.

1 reference

12 December 2020

Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

1 reference

12 December 2020

The epidemiology of generalized anxiety disorder in Europe

1 reference

12 December 2020

Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments.

1 reference

12 December 2020

The impact of generalized anxiety disorder and stressful life events on risk for major depressive episodes

1 reference

12 December 2020

Cost of anxiety disorders: impact of comorbidity.

1 reference

12 December 2020

Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression.

1 reference

12 December 2020

Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder

1 reference

12 December 2020

The long-term clinical course of generalized anxiety disorder

1 reference

12 December 2020

Drug development for anxiety disorders: new roles for atypical antipsychotics.

1 reference

12 December 2020

Lost productivity among full-time workers with mental disorders

1 reference

12 December 2020

A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care

1 reference

12 December 2020

Costs of nine common mental disorders: implications for curative and preventive psychiatry.

1 reference

12 December 2020

Infrequency of "pure" GAD: impact of psychiatric comorbidity on clinical course.

1 reference

12 December 2020

Impairment and quality of life in individuals with generalized anxiety disorder

1 reference

12 December 2020

Traumatic stress: effects on the brain

1 reference

12 December 2020

A New Depression Scale Designed to be Sensitive to Change

1 reference

12 December 2020

Cognitive therapy of anxiety disorders

1 reference

12 December 2020

The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample

1 reference

12 December 2020

Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs

1 reference

12 December 2020

The hospital anxiety and depression scale

1 reference

12 December 2020

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

1 reference

12 December 2020

Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.

1 reference

12 December 2020

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study

1 reference

12 December 2020

Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients

1 reference

12 December 2020

A population-based twin study of generalized anxiety disorder in men and women

1 reference

12 December 2020

Comorbidity in generalized anxiety disorder: impact and implications.

1 reference

12 December 2020

Psychological therapies for generalised anxiety disorder

1 reference

12 December 2020

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms

1 reference

12 December 2020

Development and validation of the Generalized Anxiety Disorder Inventory (GADI)

1 reference

12 December 2020

Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication

1 reference

12 December 2020

New developments in the neurobiological basis of anxiety disorders

1 reference

12 December 2020

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

1 reference

12 December 2020

The effects of co-morbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys. International Consortium in Psychiatric Epidemiology.

1 reference

12 December 2020

Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS).

1 reference

12 December 2020

Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder.

1 reference

12 December 2020

Human and economic burden of generalized anxiety disorder

1 reference

12 December 2020

Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure

1 reference

12 December 2020

Generalized anxiety disorder in primary care: emerging issues in management and treatment.

1 reference

12 December 2020

Treatments for generalized anxiety disorder

1 reference

12 December 2020

Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders

1 reference

12 December 2020

Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study

1 reference

12 December 2020

Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients.

1 reference

12 December 2020

Pregabalin: in the treatment of generalised anxiety disorder

1 reference

12 December 2020

Improving adherence to antipsychotic pharmacotherapy

1 reference

12 December 2020

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

12 December 2020

Open-label pilot study of ziprasidone for refractory generalized anxiety disorder

1 reference

12 December 2020

Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study

1 reference

12 December 2020

Anxiety and hippocampus volume in the rat.

1 reference

12 December 2020

Diagnosis and management of generalized anxiety disorder

1 reference

12 December 2020

A retrospective pooled analysis of duloxetine safety in 23,983 subjects

1 reference

12 December 2020

[Generalized anxiety disorder with comorbidity. Treatment with pregabalin]

1 reference

12 December 2020

Prevalence of mental disorders and psychosocial impairments in adolescents and young adults

1 reference

12 December 2020

Azapirones for generalized anxiety disorder

1 reference

12 December 2020

Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission

1 reference

12 December 2020

Evidence for genetic influences common and specific to symptoms of generalized anxiety and panic.

1 reference

12 December 2020

Assessing impairment in patients with panic disorder: the Sheehan Disability Scale

1 reference

12 December 2020

Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder

1 reference

12 December 2020

One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample

1 reference

12 December 2020

Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.

1 reference

12 December 2020

Behavioural inhibition, attachment and anxiety in children of mothers with anxiety disorders.

1 reference

12 December 2020

The cost of treating anxiety: the medical and demographic correlates that impact total medical costs.

1 reference

12 December 2020

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

12 December 2020

Treatment of anxiety disorders to remission.

1 reference

12 December 2020

An open-label trial of risperidone augmentation for refractory anxiety disorders

1 reference

12 December 2020

Psychotherapy for generalized anxiety disorder.

1 reference

12 December 2020

Generalized anxiety disorder: prevalence, burden, and cost to society.

1 reference

12 December 2020

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

1 reference

12 December 2020

Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder

1 reference

12 December 2020

The associations between psychopathology and being overweight: a 20-year prospective study.

1 reference

12 December 2020

Generalized anxiety and depression in primary care: prevalence, recognition, and management.

1 reference

12 December 2020

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

1 reference

12 December 2020

Treatment of anxiety disorders with venlafaxine XR.

1 reference

12 December 2020

Prevention of relapse in generalized anxiety disorder by escitalopram treatment

1 reference

12 December 2020

Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome

1 reference

12 December 2020

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

12 December 2020

Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys

1 reference

12 December 2020

Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain

1 reference

12 December 2020

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

1 reference

12 December 2020

Anxiety sensitivity, anxiety frequency and the prediction of fearfulness

1 reference

12 December 2020

Why do people with anxiety disorders become depressed? A prospective-longitudinal community study.

1 reference

12 December 2020

Stress-induced change of mitochondria membrane potential regulated by genomic and non-genomic GR signaling: a possible mechanism for hippocampus atrophy in PTSD.

1 reference

12 December 2020

Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey.

1 reference

12 December 2020

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

1 reference

12 December 2020

Risk factors for suicidality in Europe: results from the ESEMED study

1 reference

12 December 2020

Antidepressants in panic disorder: clinical and preclinical mechanisms

1 reference

12 December 2020

10.2165/00023210-200923020-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

1013752074

0 references

1 reference